AMGN
Amgen Inc.
Set alert
- YTD
- +42.38%
- 1 year
- +59.59%
- Open
- 470.00
- Prev close
- 460.73
- Mkt cap
- 251.94B
- Vol
- 3.29M
- Avg vol
- 2.78M
- EPS
- 16.10
- P/E
- 28.94
- Div yield
- 2.19%
More statistics
- Low
- 465.33
- High
- 475.65
- Forward P/E
- 19.03
- Beta
- 0.41
- Short ratio
- 4.35
- Inst. own
- 85.07%
- Dividend
- 10.08
- Ex-div date
- Nov 19, 2026
- Earnings
- Nov 3, 2026
- 50-d avg
- 419.32
- 200-d avg
- 374.10
- 1y target
- 397.32
Key statistics
- Market cap
- 251.94B
- Enterprise value
- 292.40B
- Trailing P/E
- 28.94
- Forward P/E
- 19.03
- PEG ratio
- 2.75
- Price / sales
- 6.61
- Price / book
- 21.55
- EPS (TTM)
- 16.10
- Beta
- 0.41
- Dividend yield
- 2.19%
- Payout ratio
- 60.87%
- Profit margin
- 22.95%
- Revenue (TTM)
- 38.09B
- Revenue growth
- 9.50%
- Free cash flow
- 8.65B
- Total cash
- 13.99B
- Total debt
- 57.30B
- Return on equity
- 91.47%
- Shares outstanding
- 540.63M
- Short % of float
- 2.48%
- 50-day average
- 419.32
- 200-day average
- 374.10
Analyst view
Consensus: hold
- Target (low)
- 225.00
- Target (mean)
- 397.32
- Target (high)
- 500.00
- Strong buy4
- Buy8
- Hold17
- Sell3
- Strong sell2
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 5.79.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 5.79 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 5.62 | 6.29 | +0.67 | +11.92% |
| Apr 30, 2026 | Mar 31, 2026 | 4.77 | 5.15 | +0.38 | +7.97% |
| Feb 3, 2026 | Dec 31, 2025 | 4.73 | 5.29 | +0.56 | +11.84% |
| Nov 4, 2025 | Sep 30, 2025 | 5.02 | 5.64 | +0.62 | +12.35% |
| Aug 5, 2025 | Jun 30, 2025 | 5.28 | 6.02 | +0.74 | +14.02% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 21, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 13, 2026 | Guggenheim | main | Neutral | Neutral |
| Oct 12, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Oct 12, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 9, 2026 | UBS | main | Buy | Buy |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- amgen.com
News
- How to Build $6,800 a Month in Dividend Income Without Selling a Single Share
- Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
- Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer
- Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?
- AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
- Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?
- AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND
- AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
- Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Your note
Sign in to keep a note on AMGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADNER JAMES E. | Officer | Stock Award(Grant) | May 4, 2026 | 30,462 |
| BRADWAY ROBERT A | Chief Executive Officer | Stock Award(Grant) | May 4, 2026 | 657,299 |
| ECKERT ROBERT ANDREW | Director | Stock Award(Grant) | May 18, 2026 | 26,251 |
| GORDON MURDO | Officer | Stock Award(Grant) | May 4, 2026 | 51,837 |
| GRAHAM JONATHAN P | General Counsel | Stock Award(Grant) | May 4, 2026 | 40,211 |
| GRIFFITH PETER H. | Chief Financial Officer | Stock Award(Grant) | May 4, 2026 | 50,706 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.13% | 49,362,016 | 23.00B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 35,250,101 | 16.43B | Jun 29, 2026 |
| State Street Corporation | 5.65% | 30,560,537 | 14.24B | Jun 29, 2026 |
| Capital World Investors | 5.38% | 29,075,329 | 13.55B | Jun 29, 2026 |
| Invesco Ltd. | 3.02% | 16,320,446 | 7.61B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.90% | 15,696,068 | 7.31B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 17,134,234 | 7.98B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 13,987,160 | 6.52B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.27% | 12,272,320 | 5.72B | Aug 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 11,292,468 | 5.26B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 7,201,561 | 3.36B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 7,005,896 | 3.26B | Aug 30, 2026 |